 |
Takeda completes acquisition of ShireTakeda Pharmaceutical Company Limited today announced the completion of its acquisition of Shire, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda no More… |
|
Takeda completes acquisition of ShireTakeda Pharmaceutical Company Limited today announced the completion of its acquisition of Shire, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda no More… |
 |
Drugmaker Shire to buy Baxalta for $32bnDrugmaker Shire clinched its six-month pursuit of Baxalta International on Monday with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. The London-listed group, which firs More… |
|
Drugmaker Shire to buy Baxalta for $32bnDrugmaker Shire clinched its six-month pursuit of Baxalta International on Monday with an agreed $32 billion cash and stock offer, catapulting it to a leading position in treating rare diseases. The London-listed group, which firs More… |
 |
Drugmaker Shire bids $30bn for BaxaltaDrugmaker Shire said on Tuesday it was seeking to buy Baxalta, a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases. The London-listed group went public wit More… |
 |
US drugmaker AbbVie offers $51bn for ShireUS drugmaker AbbVie raised its offer for London-listed hyperactivity and rare diseases specialist Shire to 30.1 billion pounds ($51.3 billion) on Tuesday, hoping to win over its reluctant target after three earlier offers were rejected. More… |
